Newly Described Autoinflammatory Diseases in Pediatric Dermatology

Pediatric Dermatology

Volumn 33, Issue 6, 2016, Pages 602-614

  Xirotagaros, Georgios ^a   Hernández Ostiz, Sergio ^a   Aróstegui, Juan Ignacio ^b   Torrelo, Antonio ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; COMPLEMENT COMPONENT C1Q; CYTOKINE RECEPTOR ANTAGONIST; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 36 RECEPTOR ANTAGONIST; PROTEASOME; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE 2 DEFICIENCY; ADENOSINE DEAMINASE DEFICIENCY; ADULT ONSET STILL DISEASE; AICARDI GOUTIERES SYNDROME; APHTHOUS STOMATITIS; AUTOINFLAMMATION AND PLCG2 ASSOCIATED ANTIBODY DEFICIENCY AND IMMUNE DYSREGULATION; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; BLAU SYNDROME; CHILBLAIN; CHILD; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; COMPLEMENT COMPONENT C1Q DEFICIENCY; COMPLEMENT DEFICIENCY; DERMATOLOGY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FAMILIAL PSORIASIS; GENE MUTATION; H SYNDROME; HEMOPHAGOCYTIC SYNDROME; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERGAMMAGLOBULINEMIA; HYPERGAMMAGLOBULINEMIA D WITH PERIODIC FEVER SYNDROME; IMMUNE DYSREGULATION; INFANT DISEASE; INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; INTERLEUKIN 36 RECEPTOR ANTAGONIST DEFICIENCY; LABORATORY DIAGNOSIS; MAJEED SYNDROME; MEVALONATE KINASE DEFICIENCY; MEVALONIC SCIDURIA; MUCKLE WELLS SYNDROME; OSTEOMYELITIS; PAPA SYNDROME; PATHOPHYSIOLOGY; PEDIATRIC DERMATOLOGY; PEDIATRICS; PFAPA SYNDROME; PHENOTYPE; PLCG2 ASSOCIATED ANTIBODY DEFICIENCY AND IMMUNE DYSREGULATION; PRIMARY FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; PRIORITY JOURNAL; PROTEASOME ASSOCIATED AUTOINFLAMMATORY SYNDROME; PSORIASIS; RECURRENT FEVER; REVIEW; SCHNITZLER SYNDROME; SKIN MANIFESTATION; STING ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; X LINKED RETICULATE PIGMENTARY DISORDER; AUTOIMMUNE DISEASE; COMPLICATION; HEREDITARY PERIODIC FEVER; INFLAMMATION; INNATE IMMUNITY; PATHOLOGY; SKIN;

AUTOIMMUNE DISEASES; CHILD; DERMATOLOGY; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; PHENOTYPE; SKIN;

EID: 84990210737     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12984     Document Type: Review

References (50)

1. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010;140:771–776.
2. Dávila-Seijo P, Hernández-Martín A, Torrelo A. Autoinflammatory syndromes for the dermatologist. Clin Dermatol 2014;32:488–501.
3. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133–144.
4. Henderson C, Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 2010;22:567–578.
5. McDermott A, Jacks J, Kessler M et al. Proteasome-associated autoinflammatory syndromes: advances in pathogenesis, clinical presentations, diagnosis, and management. Int J Dermatol 2015;54:121–129.
6. Gomes AV. Genetics of proteasome diseases. Scientifica (Cairo) 2013;2013:637629.
7. Krüger E, Kloetzel PM. Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme. Curr Opin Immunol 2012;24:77–83.
8. Liu Y, Ramot Y, Torrelo A et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012;64:895–907.
9. Brehm A, Liu Y, Sheikh A et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 2015;125:4196–4211.
10. Torrelo A, Patel S, Colmenero I et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol 2010;62:489–495.
11. Torrelo A, Colmenero I, Requena L et al. Histologic and immunohistochemical features of the skin lesions in CANDLE syndrome. Am J Dermatopathol 2015;37:517–522.
12. Kanazawa N. Nakajo-Nishimura syndrome: an autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy. Allergol Int 2012;61:197–206.
13. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17:2619–2627.
14. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 2010;6:40–49.
15. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258–267.
16. Richards KH, Macdonald A. Putting the brakes on the anti-viral response: negative regulators of type I interferon (IFN) production. Microbes Infect 2011;13:291–302.
17. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011;1238:91–98.
18. Liu Y, Jesus AA, Marrero B et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014;371:507–518.
19. Abe J, Izawa K, Nishikomori R et al. Heterozygous TREX1 pAsp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus. Rheumatology 2013;52:406–408.
20. Aicardi J, Goutières F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984;15:49–54.
21. Fauré S, Bordelais I, Marquette C et al. Aicardi-Goutiè syndrome: monogenic recessive disease, genetically heterogeneous disease, or multifactorial disease? Clin Genet 1999;56:149–153.
22. Stephenson JB. Aicardi-Goutières syndrome (AGS). Eur J Paediatr Neurol 2008;12:355–358.
23. Dale RC, Gornall H, Singh-Grewal D et al. Familial Aicardi-Goutières syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures. Am J Med Genet A 2010;152A:938–942.
24. Juern A, Robbins A, Galbraith S et al. Aicardi-Goutières syndrome: cutaneous, laboratory, and radiologic findings: a case report. Pediatr Dermatol 2010;27:82–85.
25. Brisman S, Gonzalez M, Morel KD. Blueberry muffin rash as the presenting sign of Aicardi-Goutières syndrome. Pediatr Dermatol 2009;26:432–435.
26. Crow YJ, Vanderver A, Orcesi S et al. Therapies in Aicardi-Goutières syndrome. Clin Exp Immunol 2014;175:1–8.
27. Tüngler V, Silver RM, Walkenhorst H et al. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutières syndrome. Br J Dermatol 2012;167:212–214.
28. Günther C, Hillebrand M, Brunk J et al. Systemic involvement in TREX1-associated familial chilblain lupus. J Am Acad Dermatol 2013;69:e179–e181.
29. Su WP, Perniciaro C, Rogers RS et al. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis 1994;54:395–399.
30. Patel S, Hardo F. Chilblain lupus erythematosus. BMJ Case Rep 2013;2013:pii: bcr2013201165.
31. Santer DM, Hall BE, George TC et al. C1q deficiency leads to the defective suppression of IFN-α in response to nucleoprotein containing immune complexes. J Immunol 2010;185:4738–4749.
32. Botto M, Kirschfink M, Macor P et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol 2009;46:2774–2783.
33. Roumenina LT, Sène D, Radanova M et al. Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J Immunol 2011;187:4369–4373.
34. Schejbel L, Skattum L, Hagelberg S et al. Molecular basis of hereditary C1q deficiency—revisited: identification of several novel disease-causing mutations. Genes Immun 2011;12:626–634.
35. Mehta P, Norsworthy PJ, Hall AE et al. SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology 2010;49:823–824.
36. Arkwright PD, Riley P, Hughes SM et al. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol 2014;133:265–267.
37. Starokadomskyy P, Gemelli T, Rios JJ et al. DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol 2016;17:495–504.
38. Fernandez-Guarino M, Torrelo A, Fernandez-Lorente M et al. X-linked reticulate pigmentary disorder: report of a new family. Eur J Dermatol 2008;18:102–103.
39. Chaisson NF, Paik J, Orbai AM. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) 2012;91:220–228.
40. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711–723.
41. Molho-Pessach V, Agha Z, Aamar S et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol 2008;59:79–85.
42. Molho-Pessach V, Lerer I, Abeliovich D et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet 2008;83:529–534.
43. Leung GP, Tse CM. The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity. Expert Opin Drug Metab Toxicol 2007;3:705–718.
44. Hsu CL, Lin W, Seshasayee D et al. Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. Science 2012;335:89–92.
45. Marina S, Broshtilova V. POEMS in childhood. Pediatr Dermatol 2006;23:145–148.
46. Prendiville J, Rogers M, Kan A. Pigmented hypertrichotic dermatosis and insulin dependent diabetes: manifestations of a unique genetic disorder? Pediatr Dermatol 2007;24:101–107.
47. Colmenero I, Molho-Pessach V, Torrelo A et al. Emperipolesis: an additional common histopathologic finding in H syndrome and Rosai-Dorfman disease. Am J Dermatopathol 2012;34:315–320.
48. Zhou Q, Yang D, Ombrello AK et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014;370:911–920.
49. Navon Elkan P, Pierce SB, Segel R et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370:921–931.
50. Zhou Q, Wang H, Schwartz DM et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 2016;48:67–73.